AstraZeneca (AZN.US) monoclonal antibody new drug approved for two indications in China
AstraZeneca (AZN.US) announced the official launch of Tezelyumab injection in China.
Zhitong Finance APP has learned that on August 17, AstraZeneca (AZN.US) announced the official launch of Tezepelumab injection in China. Tezepelumab is a biologic used to treat severe asthma, overcoming phenotype and biomarker level restrictions, and targets thymic stromal lymphopoietin (TSLP).
In March 2026, based on positive results from the DIRECTION and WAYPOINT Phase III clinical studies, Tezepelumab was approved in China for two indications: maintenance treatment for severe asthma in adults and adolescents aged 12 years and above; and, in combination with intranasal corticosteroids, for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease cannot be adequately controlled with systemic corticosteroids and/or surgery.
Tezepelumab is a human monoclonal antibody jointly developed by AstraZeneca and Amgen, capable of inhibiting the activity of TSLP. TSLP is a key epithelial cytokine upstream of multiple inflammatory cascades, playing a crucial role in the initiation and persistence of allergic, eosinophilic, and epithelium-driven inflammation associated with severe asthma, chronic rhinosinusitis with nasal polyps, and other inflammatory diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US stock index adjustments to take effect next Monday: Bloom Energy (BE.US) and Everpure (P.US) to be included in S&P 500, changes also for mid- and small-cap stocks
Bloom Energy, Illumina, and Everpure will be included in the S&P 500 index, while several other companies will be added to the S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices.
Is the Federal Reserve repeating the 2022-style rate hikes? Bank of America warns: Rates may return above 5%, suggests shorting two-year U.S. Treasuries.
Bank of America warns: With Waller at the helm, the Federal Reserve may raise interest rates above 5%, potentially repeating the events of 2022.
OpenAI is expected to burn over $278 billion in cash by 2030, with a revenue target of $350 billion over the same period.
OpenAI is expected to generate up to $278 billion in negative free cash flow over the next five years, driven solely by computing power and infrastructure, with cumulative spending projected to reach approximately $856 billion by 2030. The company anticipates revenue of $350 billion in 2030 and $36 billion in 2026, with total revenue from 2026 to 2030 amounting to around $840 billion.
Crypto prices
More
